Search results for "infarct"

showing 10 items of 1223 documents

The Full Revasc (Ffr-gUidance for compLete non-cuLprit REVASCularization) Registry-based randomized clinical trial

2021

Publisher Copyright: © 2021 Background: Complete revascularization in ST elevation myocardial infarction (STEMI) patients with multivessel disease has resulted in reduction in composite clinical endpoints in medium sized trials. Only one trial showed an effect on hard clinical endpoints, but the revascularization procedure was guided by angiographic evaluation of stenosis severity. Consequently, it is not clear how Fractional Flow Reserve (FFR)-guided percutaneous coronary intervention (PCI) affects hard clinical endpoints in STEMI. Methods and Results: The Ffr-gUidance for compLete non-cuLprit REVASCularization (FULL REVASC) – is a pragmatic, multicenter, international, registry-based rand…

MaleEmergency Medical Servicesmedicine.medical_treatmentFractional flow reserve030204 cardiovascular system & hematologyCoronary AngiographyGUIDELINESSeverity of Illness IndexANGIOGRAPHYDISEASElaw.invention0302 clinical medicineRandomized controlled triallawFRACTIONAL FLOW RESERVEClinical endpointMedicineCardiac and Cardiovascular Systems030212 general & internal medicineRegistriesKardiologiMiddle Aged3. Good healthFractional Flow Reserve MyocardialOutcome and Process Assessment Health CareSurgery Computer-AssistedCardiologyFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationCulpritLESION03 medical and health sciencesPercutaneous Coronary InterventionInternal medicineHumanscardiovascular diseasesMortalityANGIOPLASTYAgedbusiness.industryCoronary StenosisELEVATION MYOCARDIAL-INFARCTIONPercutaneous coronary interventionmedicine.disease3126 Surgery anesthesiology intensive care radiologyStenosis3121 General medicine internal medicine and other clinical medicineConventional PCIST Elevation Myocardial Infarctionbusiness
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct

''Effect of stroke on arginase expression and localization in the rat brain''

2013

Quirie, Aurore | Demougeot, C. Eline | Bertrand, Nathalie | Mossiat, Claude | Garnier, Philippe | Marie, Christine | Prigent-Tessier, Anne; International audience; ''Because arginase and nitric oxide (NO) synthases (NOS) compete to degrade l-arginine, arginase plays a crucial role in the modulation of NO production. Moreover, the arginase 1 isoform is a marker of M2 phenotype macrophages that play a key role in tissue remodeling and resolution of inflammation. While NO has been extensively investigated in ischemic stroke, the effect of stroke on the arginase pathway is unknown. The present study focuses on arginase expression/activity and localization before and after (1, 8, 15 and 30days) …

MaleGene Expressionchemistry.chemical_compound0302 clinical medicineNeurotrophic factorsMACROPHAGESIN-VIVONeuronsAXONAL REGENERATION0303 health sciencesGlial fibrillary acidic proteinGeneral NeuroscienceBrainGLIAL RESPONSESCerebral InfarctionStrokeNitric oxide synthaseArginasemedicine.anatomical_structureBiochemistry[ SCCO.NEUR ] Cognitive science/NeuroscienceARGININE METABOLISMmedicine.symptom2'-DIPYRIDYLmedicine.medical_specialtyCentral nervous systemIRON CHELATOR 2InflammationBiologyFOCAL ISCHEMIANitric oxideLesion03 medical and health sciencesInternal medicineGlial Fibrillary Acidic ProteinmedicineAnimalsRats WistarNITRIC-OXIDE SYNTHASE030304 developmental biologyArginaseCEREBRAL-ISCHEMIABrain-Derived Neurotrophic Factor[SCCO.NEUR]Cognitive science/NeuroscienceCENTRAL-NERVOUS-SYSTEM''NITRIC-OXIDE SYNTHASERatsEndocrinologychemistryAstrocytesbiology.proteinMACROPHAGES''030217 neurology & neurosurgery
researchProduct

Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome

2014

Background Geriatric conditions may predict outcomes beyond age and standard risk factors. Our aim was to investigate a wide spectrum of geriatric conditions in survivors after an acute coronary syndrome. Methods A total of 342 patients older than 65 years were included. At hospital discharge, 5 geriatric conditions were evaluated: frailty (Fried and Green scores), physical disability (Barthel index), instrumental disability (Lawton-Brody scale), cognitive impairment (Pfeiffer questionnaire), and comorbidity (Charlson and simple comorbidity indexes). The outcomes were postdischarge mortality and the composite of death/myocardial infarction during a 30-month median follow-up. Results Seventy…

MaleGerontologyAcute coronary syndromemedicine.medical_specialtyFrail ElderlyMyocardial InfarctionComorbidityRisk AssessmentCohort StudiesRisk FactorsInternal medicineActivities of Daily LivingmedicineHumansProspective StudiesMyocardial infarctionAcute Coronary SyndromeGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overHand StrengthReceiver operating characteristicProportional hazards modelbusiness.industryHazard ratioPrognosismedicine.diseaseComorbidityROC CurveArea Under CurveMultivariate AnalysisExercise TestFemaleCognition DisordersCardiology and Cardiovascular MedicineRisk assessmentbusinessCohort studyAmerican Heart Journal
researchProduct

Prothrombotic gene variants as risk factors of acute myocardial infarction in young women

2012

Abstract Background Acute myocardial infarction (AMI) in young women represent an extreme phenotype associated with a higher mortality compared with similarly aged men. Prothrombotic gene variants could play a role as risk factors for AMI at young age. Methods We studied Factor V Leiden, FII G20210A, MTHFR C677T and beta-fibrinogen -455G>A variants by real-time PCR in 955 young AMI (362 females) and in 698 AMI (245 females) patients. The data were compared to those obtained in 909 unrelated subjects (458 females) from the general population of the same geographical area (southern Italy). Results In young AMI females, the allelic frequency of either FV Leiden and of FII G20210A was signif…

MaleHomocysteineMyocardial Infarctionlcsh:Medicinegene variantsprothrombotic gene variantsAMIchemistry.chemical_compoundGene FrequencyRisk FactorsgenderMyocardial infarctionMedicine(all)GeneticsYoung AMI Gender AMI Gene variants Mutations Prothrombotic variants Genetic predispositioneducation.field_of_studyprothrombotic variantsbiologyHomozygoteFactor VGeneral MedicineFemaleProthrombinyoung AMIAdultmedicine.medical_specialtyPopulationyoung AMI gender AMI gene variants mutations prothrombotic variants genetic predisposition.Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicineFactor V LeidenGenetic predispositionHumansGenetic Predisposition to Diseasecardiovascular diseaseseducationAllele frequencyAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchlcsh:RFactor VThrombosismutationsmedicine.diseasechemistryMethylenetetrahydrofolate reductasebiology.proteinbusinessgenetic predispositionJournal of Translational Medicine
researchProduct

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

2018

IF 16.834 (2017); International audience; BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was…

MaleInotropeILL PATIENTSCardiac index030204 cardiovascular system & hematologyLACTATE0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesSUPPORTTISSUE OXYGENATIONVasoconstrictor AgentsProspective StudiesMyocardial infarctionCardiogenic shockcardiogenic shockMiddle Aged3. Good healthEpinephrineCardiologyHEARTFemaleTRIALFranceCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyShock Cardiogenicacute myocardial infarctionvasopressornorepinephrineEXTRACORPOREAL MEMBRANE-OXYGENATIONNorepinephrine (medication)03 medical and health sciencesDouble-Blind MethodInternal medicineHeart rateMANAGEMENTmedicineHumansepinephrineAgedbusiness.industrySeptic shockMORTALITYSEPTIC SHOCKHemodynamics030208 emergency & critical care medicinemedicine.disease3121 General medicine internal medicine and other clinical medicinebusiness
researchProduct

Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes

2009

Abstract Background Low lymphocyte count (LLC), a surrogate for inflammation, has emerged as a potential risk factor for cardiovascular outcomes, especially new ischemic events. To identify patients with non-ST segment elevation acute coronary syndromes (NSTEACS) who benefit from an invasive revascularization strategy remains a challenge. We sought to determine if patients with high-risk NSTEACS who exhibited LLC have a greater reduction in long-term post-discharge myocardial infarction (MI) when managed under a revascularization invasive strategy (RIS) as compared with conservative strategy (CS). Methods Nine hundred seventy two consecutive patients with high-risk NSTEACS were treated unde…

MaleInvasive strategymedicine.medical_specialtyLymphocytemedicine.medical_treatmentMyocardial InfarctionRevascularizationElectrocardiographyRisk FactorsLymphopeniaInternal medicineMyocardial RevascularizationInternal MedicineHumansMedicineST segmentLymphocyte CountMyocardial infarctionAcute Coronary SyndromeLow lymphocyte countAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelPrognosismedicine.diseaseTreatment Outcomemedicine.anatomical_structureQuartileCardiologyFemalebusinessEuropean Journal of Internal Medicine
researchProduct

Neuroprotective effect of ceftriaxone on the penumbra in a rat venous ischemia model.

2012

Glutamate transporter-1 (GLT-1) maintains low concentrations of extracellular glutamate by removing glutamate from the extracellular space. It is controversial, however, whether upregulation of GLT-1 is neuroprotective under all ischemic/hypoxic conditions. Recently, a neuroprotective effect of preconditioning with a β-lactam antibiotic ceftriaxone (CTX) that increases expression of GLT-1 has been reported in animal models of focal ischemia. On the other hand, it is said that CTX does not play a neuroprotective role in an in vitro study. Thus, we examined the effect of CTX on ischemic injury in a rat model of two-vein occlusion (2VO). This model mimics venous ischemia during, e.g. tumor sur…

MaleIschemiaAMPA receptorPharmacologyNeuroprotectionReceptors N-Methyl-D-AspartateBrain IschemiaPotassium Chloridechemistry.chemical_compoundMedicineAnimalsDrug InteractionsReceptors AMPAKainic Acidbusiness.industryGABAA receptorGeneral NeuroscienceCeftriaxoneCortical Spreading DepressionGlutamate receptorCerebral Infarctionmedicine.diseaseReceptors GABA-AAnti-Bacterial AgentsRatsNeuroprotective AgentsMuscimolchemistryExcitatory Amino Acid Transporter 2Cortical spreading depressionAnesthesiaNMDA receptorbusinessNeuroscience
researchProduct

Postconditioning or preconditioning, which should be promoted for protecting from ischemic reperfusion injury? Response to letter IJC-D-14-02875

2014

MaleIschemic reperfusion injurymedicine.medical_specialtybusiness.industryMicrocirculationMyocardial InfarctionMyocardial Reperfusionmedicine.diseaseDisease Models AnimalInternal medicineCardiologyAnimalsHumansMedicineFemaleMyocardial infarctionIschemic PostconditioningCardiology and Cardiovascular MedicinebusinessPerfusionInternational Journal of Cardiology
researchProduct

Chronic bronchitis without airflow obstruction, asthma and rhinitis are differently associated with cardiovascular risk factors and diseases

2019

Background and objectives Cardiovascular and respiratory diseases can frequently coexist. Understanding their link may improve disease management. We aimed at assessing the associations of chronic bronchitis (CB), asthma and rhinitis with cardiovascular diseases and risk factors in the general population. Methods We used data collected in the Gene Environment Interactions in Respiratory Diseases study, an Italian multicentre, multicase-control study. Among 2463 participants (age 21–86, female 50%) who underwent standardized interviews, skin prick and lung function tests, we identified 254 cases of CB without airflow obstruction, 418 cases of asthma without CB, 959 cases of rhinitis alone, a…

MaleLUNG-DISEASEChronic bronchitisPulmonologyEpidemiologyBlood PressureCardiovascular Medicine030204 cardiovascular system & hematologyVascular Medicine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractCohort StudiesPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMedicine and Health SciencesOdds Ratiochronic bronchitiLungRhinitisAged 80 and overeducation.field_of_studyAlcohol ConsumptionMultidisciplinaryQRHeartMiddle AgedCardiovascular diseaseCBRespiratory Function Tests3. Good healthPREVALENCE[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBronchitis ChronicALLERGIC RHINITISINTERMITTENT CLAUDICATIONCardiovascular DiseasesHypertensionBronchitisMedicinechronic bronchitisFemaleAnatomymedicine.symptomResearch ArticleAdultmedicine.medical_specialtySciencePopulationbody mass indexSettore MED/10 - Malattie Dell'Apparato RespiratorioDIAGNOSISelderlychronic obstructive pulmonary diseaseYoung Adult03 medical and health sciencesHeart disorderBMI[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineConfidence IntervalsmedicineHumansCOPDCORONARY-HEART-DISEASEBronchitiseducationNutritionAgedAsthmaCORONARY-HEART-DISEASE; ALLERGIC RHINITIS; INTERMITTENT CLAUDICATION; MYOCARDIAL-INFARCTION; MUCUS HYPERSECRETION; CIGARETTE-SMOKING; LUNG-DISEASE; DIAGNOSIS; ATHEROSCLEROSIS; PREVALENCEbusiness.industryBiology and Life SciencesOdds ratioRhinologyasthmamedicine.diseaseIntermittent claudicationDietOtorhinolaryngology030228 respiratory systemMYOCARDIAL-INFARCTIONATHEROSCLEROSISMUCUS HYPERSECRETION[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMedical Risk FactorsCase-Control StudiesRelative riskNasal DiseasesCardiovascular Anatomy[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCIGARETTE-SMOKINGbusinessBMI body mass index; CB chronic bronchitis; COPD chronic obstructive pulmonary disease;
researchProduct